Phase 1b/2 Study of Binimetinib in Combination With Nivolumab (NIVO) or NIVO Plus Ipilimumab in Patients With Previously Treated Microsatellite-Instable Metastatic Colorectal Cancer With RAS Mutation

Johanna Bendell,1 Scott Kopetz,2 Mark R. Middleton,3 P. Taylor Eves,4 Adam Boyd,4 Susan Perrine,4 Jan H. M. Schellens5

1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; 2Scott Kopetz, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3University of Oxford, Oxford, UK; 4Amryl BioPharma Inc., Boulder, CO, USA; 5susan.perrine@arraybiopharma.com; susan.perrine@arraybiopharma.com; Netherlands Cancer Institute, Amsterdam, Netherlands.

INTRODUCTION

- Approximately 60% of all patients with metastatic colorectal cancer (CRC) are RAS wild type and 10-20% have RAS mutations.
- Preclinical and clinical data recently indicate that combining MEK inhibition with immunotherapy in MSS mCRC patients may provide significant antitumor activity.

PHASE 1 OVERVIEW

- Multicenter, open-label, phase 1b/2 study conducted in Belgium, the Netherlands, Spain, the United Kingdom, and the United States (Figure 2).
- Study started October 4, 2017. Study is currently recruiting participants for the phase 1 portion of the study.
- Any eligibility criteria are described in Table 1.

PHASE 2

- Objectives
  - Investigate the antitumor activity, safety, and pharmacokinetics (PK) of BINI in combination with NIVO in previously treated MSS mCRC patients compared with either agent alone in patients with RAS wild-type tumors.
- Key inclusion criteria
  - Measurable, histologically or cytologically confirmed MSS mCRC with RAS wild-type tumors.
  - No prior treatment with MEK inhibitor.
- Key exclusion criteria
  - History of thromboembolic or cerebrovascular events.
  - History of drug-resistant or drug-refractory tumors.

STUDY OVERVIEW (continued)

Table 1: Key Inclusion and Exclusion Criteria

<table>
<thead>
<tr>
<th>Key Inclusion Criteria</th>
<th>Key Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measurable, histologically or cytologically confirmed MSS mCRC</td>
<td>History of drug-resistant or drug-refractory tumors</td>
</tr>
<tr>
<td>RAS wild-type tumors</td>
<td>History of drug-resistant or drug-refractory tumors</td>
</tr>
<tr>
<td>No prior treatment with MEK inhibitor</td>
<td>History of drug-resistant or drug-refractory tumors</td>
</tr>
<tr>
<td>No prior treatment with NIVO</td>
<td>History of drug-resistant or drug-refractory tumors</td>
</tr>
</tbody>
</table>

Endpoints:

- Phase 1b: objectives (Table 2).
- Phase 2: objectives (Table 3).

DISCLOSURES

(See disclosures online at www.jco.org for more information.)

REFERENCES


STUDY OVERVIEW (continued)